The Truth About Premature Ejaculation

A new drug is in clinical trials and may offer hope for men suffering from premature ejaculation.  A press release today revealed (pre-clinical)  trials for a drug called NHo2D.  According to the company (NeuroHealing Pharmaceuticals), it is a novel mechanism. We are not sure how novel or where it is novel and if the drug relies on SSRI’s like the ones found in anti-depressants or if the mechanism is completely new.

NeuroHealing Pharmaceuticals, a private, clinical stage company developing innovative drug treatments for specialty indications based on repositioning neurologically active compounds, announces the formation of a Medical Advisory Board (MAB) to assist the company in the clinical development of NH02D, its novel mechanism of action, drug candidate for the treatment of premature ejaculation (PE).

NH02D is a neurologically active, orally administered drug that is being developed for on-demand treatment of premature ejaculation. During testing of NH02D in healthy volunteers for another indication, the drug was unexpectedly reported to delay ejaculation during sexual activity. Subsequently, the effectiveness of NH02D has been demonstrated in a validated animal model of premature ejaculation in collaboration with Dr. Lesley Marson at the University of North Carolina.

Premature ejaculation is the most prevalent male sexual disorder affecting up to 30 percent of sexually active men and is even more prevalent than erectile dysfunction (a $3.8 billion market in 2008). Currently, there are no FDA-approved products available for the treatment of this disorder in the United States.

NeuroHealing Pharmaceuticals, Inc. is a clinical stage private company developing innovative treatments for specialty indications based on repositioning neurologically active compounds. Clinical stage programs include: NH001 (phase II), a dopaminergic agent to help post traumaticbrain injury patients to emerge from a coma, vegetative or minimally consciousness state; NH004 (phase II), an anticholinergic agent in a convenient intra-orally muco-adhesive dissolving film to help treat motorneuron disease patients who suffer from sialorrhea (drooling); and NH02D, a neurologically active compound to treat premature ejaculation.